The life sciences industry has significant capital it can deploy for mergers and acquisitions in 2024, with an estimated $1.37tn on hand, according to the EY M&A Firepower report released on 8 January. Combined with factors that should drive deep-pocketed biopharma companies to seek non-organic growth, EY anticipates a year of significant M&A activity in 2024, Arda Ural, one of the report’s authors, told Scrip.
Biopharma Has Money To Spend On M&A, EY Says – As Well As Need
Upcoming patent expirations are increasing the sector’s need to acquire candidates and products that can deliver near-term revenues, driving up valuations, EY’s 2024 Firepower report says.
More from Strategy
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.